These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 6305532

  • 1. The influence of molecular form of local anesthetic-type antiarrhythmic agents on reduction of the maximum upstroke velocity of canine cardiac Purkinje fibers.
    Gintant GA, Hoffman BF, Naylor RE.
    Circ Res; 1983 Jun; 52(6):735-46. PubMed ID: 6305532
    [Abstract] [Full Text] [Related]

  • 2. Reduction of Vmax by QX-314 and benzocaine in neonatal and adult canine cardiac Purkinje fibers.
    Spinelli W, Danilo P, Rosen MR.
    J Pharmacol Exp Ther; 1988 Apr; 245(1):381-7. PubMed ID: 3361451
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Electrophysiological effects of tocainide on canine subendocardial Purkinje fibers surviving infarction.
    Kinnaird AA, Man RY.
    Eur J Pharmacol; 1986 May 13; 124(1-2):135-41. PubMed ID: 3087761
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Frequency-dependent effects of several class I antiarrhythmic drugs on Vmax of action potential upstroke in canine cardiac Purkinje fibers.
    Varro A, Elharrar V, Surawicz B.
    J Cardiovasc Pharmacol; 1985 May 13; 7(3):482-92. PubMed ID: 2410678
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The interaction of cycle length with the electrophysiological effect of lidocaine, tocainide and verapamil on canine Purkinje fibers.
    Kinnaird AA, Man RY.
    Eur J Pharmacol; 1984 Mar 16; 99(1):63-71. PubMed ID: 6426981
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Barucainide, a novel class Ib antiarrhythmic agent with a slow kinetic property: electrophysiologic observations in isolated canine and rabbit cardiac muscle.
    Takanaka C, Singh BN.
    Am Heart J; 1990 May 16; 119(5):1050-60. PubMed ID: 2330863
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Modification of Vmax of canine cardiac Purkinje fibers and of the effects of lidocaine by SC-72-14.
    Morikawa Y, Meiri H, Spinelli W, Rosen MR, Robinson RB.
    Circ Res; 1985 Sep 16; 57(3):354-61. PubMed ID: 2411443
    [Abstract] [Full Text] [Related]

  • 14. Modification of the electrophysiologic matrix by antiarrhythmic drugs.
    Hoffman BF.
    J Am Coll Cardiol; 1985 Jun 16; 5(6 Suppl):28B-30B. PubMed ID: 3923078
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Molecular determinants of drug access to the receptor site for antiarrhythmic drugs in the cardiac Na+ channel.
    Qu Y, Rogers J, Tanada T, Scheuer T, Catterall WA.
    Proc Natl Acad Sci U S A; 1995 Dec 05; 92(25):11839-43. PubMed ID: 8524860
    [Abstract] [Full Text] [Related]

  • 20. Electrophysiologic properties of a new antiarrhythmic drug--tocainide.
    Moore EN, Spear JF, Horowitz LN, Feldman HS, Moller RA.
    Am J Cardiol; 1978 Apr 05; 41(4):703-9. PubMed ID: 645575
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.